Cardiol Therapeutics (CRDL) Research & Development (2020 - 2026)

Cardiol Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• Quarterly Research & Development rose 37.83% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (up 6.26% YoY) and the FY2025 annual result came in at $10.1 million, changed 0.22% from the prior year.
• Research & Development was $3.6 million for Q1 2026 at Cardiol Therapeutics, up from $2.0 million in the prior quarter.
• Across five years, Research & Development topped out at $4.1 million in Q4 2022 and bottomed at $1.9 million in Q3 2023.
• A 5-year average of $2.9 million and a median of $3.0 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development surged 105.1% — and 2023, when it tumbled 50.74%.
• Cardiol Therapeutics' Research & Development stood at $4.1 million in 2022, then slipped by 28.29% to $3.0 million in 2023, then increased by 2.0% to $3.0 million in 2024, then plunged by 35.03% to $2.0 million in 2025, then jumped by 83.5% to $3.6 million in 2026.
• Business Quant data shows CRDL's Research & Development at $3.6 million in Q1 2026, $2.0 million in Q4 2025, and $3.5 million in Q3 2025.